Epigenomics and VSA receive approval to market Epi proColon
“The Epigenomics assay enables VSA to extend its market leading efforts to improve access to colorectal cancer screening and reduce the colorectal cancer burden in Argentina,” said Luis Israel, CEO of VSA, “Due to late detection, mortality rates from colorectal cancer are still among the highest for males and females in our country, so we have made the launch and roll-out of the blood based assay a priority.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.